With clinical trials bringing the industry one step closer to making psychedelic medicine mainstream, Mydecine announced that it has completed the world’s first international legal export of dried psilocybin mushrooms. Joshua Bartch, CEO and Chairman of Mydecine, added, “this milestone is significant to our 2021 goals as we are now able to access a quality source of much-needed product for both our own research purposes, as well as provide CGMP naturally-derived psilocybin to sell and transfer to other licensed research facilities around the globe.”

Here’s a summary of this week’s news:

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain

Mydecine has completed the world’s first international legal export of dried psilocybin mushrooms from a private mycology-focused research and cultivation facility in Jamaica.

NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data

NeonMind Biosciences Inc. has filed four new provisional patent applications with the United States Patent and Trademark Office to protect initial data obtained during NeonMind’s preclinical trial.

PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract Research, Development & Manufacturing Organization

“We are pleased to have moved our first production process from the laboratories of Dr. J. Andrew Jones at Miami University to a commercial development facility to scale production of our proprietary biosynthetic psilocybin ahead of clinical trials,” said Evan Levine, Chief Executive Officer of PsyBio.

Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters the pre-implementation stage.

Awakn Announces Exclusive License Deal with the University of Exeter to Commercialise the ‘Ketamine in the Reduction of Alcoholic Relapse’ (KARE) Intervention Validated in Phase II Clinical Trial

The study started in 2016, finished in 2020, and included 96 participants, funded by the Medical Research Council. The primary endpoints of the Phase II trial were percentage days abstinent and relapse at 6 months, with secondary endpoints including depressive symptoms, craving, and quality of life.

Psyched Wellness Provides Update on Pre-Clinical Trial of Its Muscimol Extract AME-1

“I am pleased to share the positive results from the individual studies that our CRO is conducting in the pre-clinical study on our behalf for AME-1,” said Jeff Stevens, CEO of Psyched Wellness. “Today’s results pushes us one step closer to our goal of applying to the FDA for a New Dietary Ingredient and to Health Canada for a Natural Health Product Number.”

Each Wednesday and Saturday, we will send you a review of the latest price movements, financial analysis, and original insights on the emerging financial landscape of the psychedelic industry.